Iofolastat I-123

Drug Profile

Iofolastat I-123

Alternative Names: 123I-MIP-1072; MIP-1072; Trofex

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator Georgetown University; Johns Hopkins University
  • Developer Progenics Pharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 14 Jun 2012 Efficacy data from a phase I trial in Prostate cancer (diagnosis) released by Molecular Insight Pharmaceuticals
  • 14 Oct 2010 Efficacy data from phase I trials for Prostate cancer diagnosis released by Molecular Insight Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top